Search results
Results from the WOW.Com Content Network
Undifferentiated connective tissue disease (UCTD) (also known as latent lupus or incomplete lupus [1]) is a disease in which the connective tissues are targeted by the immune system. It is a serological and clinical manifestation of an autoimmune disease .
But how does lupus affect all these organs? Well usually the immune system protects the body’s tissues from invaders, but lupus is an autoimmune disease, which means that immune cells start attacking the very tissues their supposed to protect. With lupus, essentially any tissue or organ can be targeted.
Lupus, formally called systemic lupus erythematosus (SLE), is an autoimmune disease in which the body's immune system mistakenly attacks healthy tissue in many parts of the body. [1] Symptoms vary among people and may be mild to severe. [ 1 ]
The Centers for Disease Control and Prevention estimates that more than 200,000 people in the U.S. have lupus, though the Lupus Foundation of America puts the total much higher: roughly 1.5 ...
Lupus erythematosus may manifest as systemic disease or in a purely cutaneous form also known as incomplete lupus erythematosus. Lupus has four main types: [citation needed] systemic; discoid; drug-induced; neonatal; Of these, systemic lupus erythematosus (also known as SLE) is the most common and serious form.
In systemic lupus there are autoantibodies to DNA, which cannot evoke a T cell response, and limited evidence for T cell responses implicates nucleoprotein antigens. In Celiac disease there are autoantibodies to tissue transglutaminase but the T cell response is to the foreign protein gliadin.
Cutaneous vasculitis is the most common type of vasulitis amongst those with systemic lupus erythematosus. [7] The clinical presentation is variable and can include superficial ulcerations, splinter hemorrhages, panniculitis, macules, erythema with necrosis or erythematous plaques, cutaneous infarction, livedo reticularis, bullous lesions of the extremities or urticaria lesions, papulonodular ...
The oral drug, brepocitinib, did not meet the primary study goal of reduction in disease activity at week 52 in patients of SLE, in which the immune system that normally helps protect the body ...